Roche, Mylan Settle Suit Over Generic Cancer Drug

Law360, New York (September 21, 2011, 7:36 PM EDT) -- Hoffmann-La Roche Inc. and Mylan Inc. on Tuesday reached a settlement over claims that Mylan infringed a Roche patent by marketing a generic version of cancer drug Xeloda.

Mylan said Wednesday that the companies had reached a settlement and licensing agreement over Mylan's production of generic capecitabine tablets, which are used as a chemotherapy agent.

The agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, Mylan said. Terms of the settlement were not disclosed.

Roche sued Canonsburg, Pa.-based Mylan...
To view the full article, register now.